{"id":77151,"date":"2026-11-17T20:01:30","date_gmt":"2026-11-17T20:01:30","guid":{"rendered":"https:\/\/www.stocktargetadvisor.com\/blog\/?p=77151"},"modified":"2026-11-17T20:01:30","modified_gmt":"2026-11-17T20:01:30","slug":"american-analyst-ratings-updates-november-16th-2026","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/","title":{"rendered":"American Analyst Ratings Updates: November 16th, 2026"},"content":{"rendered":"<h2><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/?p=77151&amp;preview=true\">Analyst Ratings (USA)<\/a><\/h2>\n<p><strong>Applied Aerospace &amp; Defense (AADX)<\/strong> \u2014 Jefferies Financial Group downgraded the stock to Hold and revised its price target from $20.00 to $10.00.<\/p>\n<p><strong>Aardvark Therapeutics (AARD)<\/strong> \u2014 Stifel Nicolaus set a price target of $2.00.<\/p>\n<p><strong>AbbVie (ABBV)<\/strong> \u2014 Barclays raised its price target from $325.00 to $335.00, maintaining an Overweight rating.<\/p>\n<p><strong>Ameris Bancorp (ABCB)<\/strong> \u2014 Raymond James Financial maintained its Market Perform rating.<\/p>\n<p><strong>AbCellera Biologics (ABCL)<\/strong> \u2014 Jefferies Financial Group maintained its Buy rating.<\/p>\n<p><strong>AbCellera Biologics (ABCL)<\/strong> \u2014 Piper Sandler raised its price target from $12.00 to $20.00, maintaining an Overweight rating.<\/p>\n<p><strong>Airbnb (ABNB)<\/strong> \u2014 Phillip Securities upgraded the stock to Hold and revised its price target from $158.00 to $184.00.<\/p>\n<p><strong>Absci (ABSI)<\/strong> \u2014 Guggenheim lowered its price target from $15.00 to $14.00, maintaining a Buy rating.<\/p>\n<p><strong>Array Digital Infrastructure (AD)<\/strong> \u2014 Royal Bank Of Canada lowered its price target from $40.00 to $33.00, maintaining a Sector Perform rating.<\/p>\n<p><strong>Array Digital Infrastructure (AD)<\/strong> \u2014 JPMorgan Chase &amp; Co. lowered its price target from $45.00 to $43.00, maintaining an Overweight rating.<\/p>\n<p><strong>Agree Realty (ADC)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $79.00 to $81.00, maintaining an Overweight rating.<\/p>\n<p><strong>ADI Global Distribution Inc. Common Stock (ADIG)<\/strong> \u2014 Truist Financial lowered its price target from $24.00 to $11.00, maintaining a Hold rating.<\/p>\n<p><strong>Addus HomeCare (ADUS)<\/strong> \u2014 Royal Bank Of Canada raised its price target from $134.00 to $141.00, maintaining an Outperform rating.<\/p>\n<p><strong>Aetherion Technologies (AETR)<\/strong> \u2014 Royal Bank Of Canada raised its price target from $1.00 to $1.75, maintaining a Sector Perform rating.<\/p>\n<p><strong>Assurant (AIZ)<\/strong> \u2014 Morgan Stanley raised its price target from $330.00 to $360.00, maintaining an Overweight rating.<\/p>\n<p><strong>Arthur J. Gallagher &amp; Co. (AJG)<\/strong> \u2014 Morgan Stanley raised its price target from $295.00 to $325.00, maintaining an Overweight rating.<\/p>\n<p><strong>Akebia Therapeutics (AKBA)<\/strong> \u2014 Piper Sandler issued a price target of $2.00, maintaining an Overweight rating.<\/p>\n<p><strong>Allstate (ALL)<\/strong> \u2014 JPMorgan Chase &amp; Co. lowered its price target from $292.00 to $291.00, maintaining an Overweight rating.<\/p>\n<p><strong>Alumis (ALMS)<\/strong> \u2014 Oppenheimer issued a price target of $28.00, maintaining an Outperform rating.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 Freedom Broker lowered its price target from $530.00 to $490.00, maintaining a Buy rating.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 Susquehanna maintained its Positive rating.<\/p>\n<p><strong>Amgen (AMGN)<\/strong> \u2014 Barclays raised its price target from $400.00 to $430.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Amrize (AMRZ)<\/strong> \u2014 Jefferies Financial Group downgraded the stock to Underperform and revised its price target from $42.80 to $35.20.<\/p>\n<p><strong>Amrize (AMRZ)<\/strong> \u2014 UBS Group raised its price target from $42.00 to $46.00, maintaining a Neutral rating.<\/p>\n<p><strong>Anika Therapeutics (ANIK)<\/strong> \u2014 B. Riley Financial maintained its Buy rating and revised its price target from $23.00 to $17.00.<\/p>\n<p><strong>Annovis Bio (ANVS)<\/strong> \u2014 Roth Capital maintained its Buy rating with a price target of $3.00.<\/p>\n<p><strong>AON (AON)<\/strong> \u2014 Morgan Stanley raised its price target from $350.00 to $385.00, maintaining an Overweight rating.<\/p>\n<p><strong>AppLovin (APP)<\/strong> \u2014 Jefferies Financial Group set a price target of $500.00, maintaining a Buy rating.<\/p>\n<p><strong>Alexandria Real Estate Equities (ARE)<\/strong> \u2014 Mizuho lowered its price target from $60.00 to $50.00, maintaining an Outperform rating.<\/p>\n<p><strong>argenex (ARGX)<\/strong> \u2014 Piper Sandler raised its price target from $1,215.00 to $1,350.00, maintaining an Overweight rating.<\/p>\n<p><strong>Ascendis Pharma A\/S (ASND)<\/strong> \u2014 Barclays raised its price target from $329.00 to $341.00, maintaining an Overweight rating.<\/p>\n<p><strong>ArriVent BioPharma (AVBP)<\/strong> \u2014 Guggenheim lowered its price target from $30.00 to $28.00, maintaining a Buy rating.<\/p>\n<p><strong>Atea Pharmaceuticals (AVIR)<\/strong> \u2014 Morgan Stanley raised its price target from $7.00 to $8.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Avalyn Pharma (AVLN)<\/strong> \u2014 Morgan Stanley lowered its price target from $57.00 to $53.00, maintaining an Overweight rating.<\/p>\n<p><strong>American Water Works (AWK)<\/strong> \u2014 Bank of America set a price target of $157.00, maintaining a Neutral rating.<\/p>\n<p><strong>Credicorp (BAP)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $482.00 to $490.00, maintaining an Overweight rating.<\/p>\n<p><strong>Banco Bradesco (BBD)<\/strong> \u2014 Itau BBA Securities downgraded the stock to Market Perform.<\/p>\n<p><strong>Best Buy (BBY)<\/strong> \u2014 Telsey Advisory Group raised its price target from $95.00 to $110.00, maintaining an Outperform rating.<\/p>\n<p><strong>KE (BEKE)<\/strong> \u2014 Citigroup maintained its Buy rating.<\/p>\n<p><strong>KE (BEKE)<\/strong> \u2014 Jefferies Financial Group maintained its Buy rating.<\/p>\n<p><strong>BILL (BILL)<\/strong> \u2014 William Blair upgraded the stock to Outperform.<\/p>\n<p><strong>Bullish (BLSH)<\/strong> \u2014 Wells Fargo &amp; Company lowered its price target from $35.00 to $28.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Belite Bio (BLTE)<\/strong> \u2014 Mizuho raised its price target from $221.00 to $230.00, maintaining an Outperform rating.<\/p>\n<p><strong>Belite Bio (BLTE)<\/strong> \u2014 Canaccord Genuity Group raised its price target from $303.00 to $314.00, maintaining a Buy rating.<\/p>\n<p><strong>Benitec Biopharma (BNTC)<\/strong> \u2014 Leerink Partners raised its price target from $18.00 to $18.27, maintaining an Outperform rating.<\/p>\n<p><strong>Benitec Biopharma (BNTC)<\/strong> \u2014 Wedbush raised its price target from $17.00 to $20.00, maintaining an Outperform rating.<\/p>\n<p><strong>BOX (BOX)<\/strong> \u2014 Citigroup raised its price target from $40.00 to $55.00, maintaining a Buy rating.<\/p>\n<p><strong>BP (BP)<\/strong> \u2014 Argus raised its price target from $50.00 to $53.00, maintaining a Buy rating.<\/p>\n<p><strong>Bragg Gaming Group (BRAG)<\/strong> \u2014 ATB Cormark Capital Markets downgraded the stock to Hold.<\/p>\n<p><strong>Brown &amp; Brown (BRO)<\/strong> \u2014 Morgan Stanley raised its price target from $55.00 to $60.00, maintaining an Underweight rating.<\/p>\n<p><strong>Bending Spoons (BSP)<\/strong> \u2014 Bank of America set a price target of $38.00, maintaining an Underperform rating.<\/p>\n<p><strong>Bit Digital (BTBT)<\/strong> \u2014 B. Riley Financial issued a price target of $3.50, maintaining a Buy rating.<\/p>\n<p><strong>Peabody Energy (BTU)<\/strong> \u2014 UBS Group upgraded the stock to Buy and revised its price target from $27.50 to $22.00.<\/p>\n<p><strong>Burlington Stores (BURL)<\/strong> \u2014 Morgan Stanley lowered its price target from $432.00 to $381.00, maintaining an Overweight rating.<\/p>\n<p><strong>BrightView (BV)<\/strong> \u2014 Oppenheimer lowered its price target from $16.00 to $13.00, maintaining an Outperform rating.<\/p>\n<p><strong>KANZHUN (BZ)<\/strong> \u2014 JPMorgan Chase &amp; Co. lowered its price target from $22.00 to $18.00, maintaining an Overweight rating.<\/p>\n<p><strong>Candel Therapeutics (CADL)<\/strong> \u2014 Citigroup lowered its price target from $26.00 to $20.00, maintaining a Buy rating.<\/p>\n<p><strong>Chubb (CB)<\/strong> \u2014 Morgan Stanley raised its price target from $360.00 to $380.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>CBRE Group (CBRE)<\/strong> \u2014 Barclays lowered its price target from $183.00 to $161.00, maintaining an Overweight rating.<\/p>\n<p><strong>Cogent Communications (CCOI)<\/strong> \u2014 Wells Fargo &amp; Company downgraded the stock to Underweight and revised its price target from $14.00 to $4.00.<\/p>\n<p><strong>Cardinal Infrastructure Group (CDNL)<\/strong> \u2014 Stifel Nicolaus downgraded the stock to Hold and revised its price target from $34.00 to $8.00.<\/p>\n<p><strong>COPT Defense Properties (CDP)<\/strong> \u2014 Wells Fargo &amp; Company lowered its price target from $41.00 to $36.00, maintaining an Overweight rating.<\/p>\n<p><strong>CDW (CDW)<\/strong> \u2014 Barclays raised its price target from $148.00 to $164.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Codexis (CDXS)<\/strong> \u2014 Stephens maintained its Overweight rating with a price target of $5.00.<\/p>\n<p><strong>Ceva (CEVA)<\/strong> \u2014 Cfra upgraded the stock to Buy.<\/p>\n<p><strong>Citizens Financial Group (CFG)<\/strong> \u2014 Cantor Fitzgerald raised its price target from $78.00 to $80.00, maintaining an Overweight rating.<\/p>\n<p><strong>Cognex (CGNX)<\/strong> \u2014 Barclays lowered its price target from $85.00 to $76.00, maintaining an Overweight rating.<\/p>\n<p><strong>Cummins (CMI)<\/strong> \u2014 Morgan Stanley lowered its price target from $761.00 to $588.00, maintaining an Overweight rating.<\/p>\n<p><strong>Cannae (CNNE)<\/strong> \u2014 Royal Bank Of Canada downgraded the stock to Sector Perform and revised its price target from $17.00 to $18.00.<\/p>\n<p><strong>Compass Diversified (CODI)<\/strong> \u2014 Raymond James Financial maintained its Market Perform rating.<\/p>\n<p><strong>Collegium Pharmaceutical (COLL)<\/strong> \u2014 Barclays lowered its price target from $48.00 to $41.00, maintaining an Overweight rating.<\/p>\n<p><strong>Concentra Group Holdings Parent (CON)<\/strong> \u2014 Truist Financial maintained its Buy rating and revised its price target from $42.00 to $50.00.<\/p>\n<p><strong>Costco Wholesale (COST)<\/strong> \u2014 Northcoast Research downgraded the stock to Neutral.<\/p>\n<p><strong>Copart (CPRT)<\/strong> \u2014 Stephens maintained its Equal Weight rating with a price target of $35.00.<\/p>\n<p><strong>Salesforce (CRM)<\/strong> \u2014 UBS Group maintained its Buy rating.<\/p>\n<p><strong>Corsair Gaming (CRSR)<\/strong> \u2014 Wedbush raised its price target from $16.00 to $17.00, maintaining an Outperform rating.<\/p>\n<p><strong>CareTrust REIT (CTRE)<\/strong> \u2014 Mizuho lowered its price target from $45.00 to $44.00, maintaining an Outperform rating.<\/p>\n<p><strong>CareTrust REIT (CTRE)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $43.00 to $44.00, maintaining an Overweight rating.<\/p>\n<p><strong>CareTrust REIT (CTRE)<\/strong> \u2014 KeyCorp lowered its price target from $46.00 to $43.00, maintaining an Overweight rating.<\/p>\n<p><strong>CareTrust REIT (CTRE)<\/strong> \u2014 Citizens Jmp maintained its Market Outperform rating with a price target of $44.00.<\/p>\n<p><strong>Corteva (CTVA)<\/strong> \u2014 KeyCorp lowered its price target from $17.00 to $14.00, maintaining an Overweight rating.<\/p>\n<p><strong>City Therapeutics (CTY)<\/strong> \u2014 Jefferies Financial Group initiated coverage with a Strong-Buy rating.<\/p>\n<p><strong>Cousins Properties (CUZ)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $34.00 to $35.00, maintaining an Overweight rating.<\/p>\n<p><strong>CVR Energy (CVI)<\/strong> \u2014 Mizuho upgraded the stock to Neutral, with a price target of $47.00.<\/p>\n<p><strong>CommVault Systems (CVLT)<\/strong> \u2014 DA Davidson maintained its Buy rating with a price target of $210.00.<\/p>\n<p><strong>CommVault Systems (CVLT)<\/strong> \u2014 Stephens maintained its Overweight rating with a price target of $205.00.<\/p>\n<p><strong>CVS Health (CVS)<\/strong> \u2014 Royal Bank Of Canada lowered its price target from $113.00 to $108.00, maintaining an Outperform rating.<\/p>\n<p><strong>Cushman &amp; Wakefield (CWK)<\/strong> \u2014 Barclays lowered its price target from $16.00 to $15.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Deere &amp; Company (DE)<\/strong> \u2014 Raymond James Financial maintained its Outperform rating.<\/p>\n<p><strong>DeFi Technologies (DEFT)<\/strong> \u2014 B. Riley Financial maintained its Buy rating and revised its price target from $0.62 to $0.64.<\/p>\n<p><strong>Dell Technologies (DELL)<\/strong> \u2014 Morgan Stanley lowered its price target from $511.00 to $403.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Dell Technologies (DELL)<\/strong> \u2014 Citigroup lowered its price target from $600.00 to $550.00, maintaining a Buy rating.<\/p>\n<p><strong>Dolby Laboratories (DLB)<\/strong> \u2014 Rosenblatt Securities lowered its price target from $85.00 to $80.00, maintaining a Buy rating.<\/p>\n<p><strong>DLocal (DLO)<\/strong> \u2014 Susquehanna maintained its Positive rating.<\/p>\n<p><strong>Dollar Tree (DLTR)<\/strong> \u2014 UBS Group raised its price target from $150.00 to $165.00, maintaining a Buy rating.<\/p>\n<p><strong>Healthpeak Properties (DOC)<\/strong> \u2014 Mizuho lowered its price target from $24.00 to $23.00, maintaining an Outperform rating.<\/p>\n<p><strong>Healthpeak Properties (DOC)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $19.00 to $20.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>DPC (DPC)<\/strong> \u2014 Morgan Stanley raised its price target from $43.00 to $47.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>DPC (DPC)<\/strong> \u2014 Barclays raised its price target from $49.00 to $50.00, maintaining an Overweight rating.<\/p>\n<p><strong>Devon Energy (DVN)<\/strong> \u2014 Raymond James Financial maintained its Strong-Buy rating.<\/p>\n<p><strong>Eagle Point Credit (ECC)<\/strong> \u2014 B. Riley Financial lowered its price target from $4.50 to $4.00, maintaining a Buy rating.<\/p>\n<p><strong>Echostar (ECHO)<\/strong> \u2014 Citigroup raised its price target from $117.00 to $139.00, maintaining a Buy rating.<\/p>\n<p><strong>Encore Capital Group (ECPG)<\/strong> \u2014 Truist Financial downgraded the stock to Hold and revised its price target from $122.00 to $115.00.<\/p>\n<p><strong>Consolidated Edison (ED)<\/strong> \u2014 Bank of America set a price target of $106.00, maintaining an Underperform rating.<\/p>\n<p><strong>Equifax (EFX)<\/strong> \u2014 Needham &amp; Company LLC raised its price target from $210.00 to $220.00, maintaining a Buy rating.<\/p>\n<p><strong>Equifax (EFX)<\/strong> \u2014 Mizuho raised its price target from $185.00 to $212.00, maintaining an Outperform rating.<\/p>\n<p><strong>Enovix (ENVX)<\/strong> \u2014 Canaccord Genuity Group issued a price target of $2.50, maintaining a Buy rating.<\/p>\n<p><strong>EOG Resources (EOG)<\/strong> \u2014 Citigroup raised its price target from $150.00 to $155.00, maintaining a Neutral rating.<\/p>\n<p><strong>EPR Properties (EPR)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $56.00 to $62.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Essential Properties Realty Trust (EPRT)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $30.00 to $32.00, maintaining an Overweight rating.<\/p>\n<p><strong>Eupraxia Pharmaceuticals (EPRX)<\/strong> \u2014 Wedbush maintained its Outperform rating.<\/p>\n<p><strong>Edwards Lifesciences (EW)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $113.00 to $121.00, maintaining an Overweight rating.<\/p>\n<p><strong>East West Bancorp (EWBC)<\/strong> \u2014 Cantor Fitzgerald raised its price target from $146.00 to $148.00, maintaining an Overweight rating.<\/p>\n<p><strong>Expand Energy (EXE)<\/strong> \u2014 The Goldman Sachs Group lowered its price target from $117.00 to $103.00, maintaining a Buy rating.<\/p>\n<p><strong>Extra Space Storage (EXR)<\/strong> \u2014 Barclays raised its price target from $172.00 to $173.00, maintaining an Overweight rating.<\/p>\n<p><strong>First BanCorp. (FBP)<\/strong> \u2014 UBS Group initiated coverage with a Neutral rating and a price target of $27.00.<\/p>\n<p><strong>Four Corners Property Trust (FCPT)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $22.00 to $23.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Adherex Technologies (FENC)<\/strong> \u2014 B. Riley Financial maintained its Buy rating and revised its price target from $18.00 to $19.00.<\/p>\n<p><strong>First Financial Bankshares (FFIN)<\/strong> \u2014 Cantor Fitzgerald lowered its price target from $34.00 to $33.00, maintaining a Neutral rating.<\/p>\n<p><strong>Figure Technology Solutions (FIGR)<\/strong> \u2014 Mizuho lowered its price target from $55.00 to $46.00, maintaining an Outperform rating.<\/p>\n<p><strong>Deep Fission (FISN)<\/strong> \u2014 ThinkEquity initiated coverage with a Buy rating.<\/p>\n<p><strong>Fiserv (FISV)<\/strong> \u2014 Robert W. Baird raised its price target from $70.00 to $85.00, maintaining an Outperform rating.<\/p>\n<p><strong>Fold (FLD)<\/strong> \u2014 Cantor Fitzgerald set a price target of $0.70, maintaining an Overweight rating.<\/p>\n<p><strong>FMC (FMC)<\/strong> \u2014 KeyCorp downgraded the stock to Sector Weight.<\/p>\n<p><strong>Federal Signal (FSS)<\/strong> \u2014 Raymond James Financial set a price target of $140.00, maintaining an Outperform rating.<\/p>\n<p><strong>Sensei Biotherapeutics (FTH)<\/strong> \u2014 HC Wainwright maintained its Buy rating with a price target of $60.00.<\/p>\n<p><strong>Sensei Biotherapeutics (FTH)<\/strong> \u2014 Needham &amp; Company LLC maintained its Buy rating with a price target of $56.00.<\/p>\n<p><strong>FrontView REIT (FVR)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $20.00 to $22.00, maintaining an Overweight rating.<\/p>\n<p><strong>First Watch Restaurant Group (FWRG)<\/strong> \u2014 DA Davidson maintained its Buy rating with a price target of $17.00.<\/p>\n<p><strong>Gemini Space Station (GEMI)<\/strong> \u2014 Mizuho lowered its price target from $7.00 to $6.00, maintaining an Outperform rating.<\/p>\n<p><strong>Gemini Space Station (GEMI)<\/strong> \u2014 Rosenblatt Securities lowered its price target from $6.00 to $4.50, maintaining a Buy rating.<\/p>\n<p><strong>Gemini Space Station (GEMI)<\/strong> \u2014 Needham &amp; Company LLC lowered its price target from $6.50 to $6.00, maintaining a Buy rating.<\/p>\n<p><strong>Gemini Space Station (GEMI)<\/strong> \u2014 The Goldman Sachs Group lowered its price target from $4.25 to $3.75, maintaining a Sell rating.<\/p>\n<p><strong>Gilead Sciences (GILD)<\/strong> \u2014 Barclays raised its price target from $145.00 to $160.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Glaukos (GKOS)<\/strong> \u2014 BTIG Research raised its price target from $234.00 to $252.00, maintaining a Buy rating.<\/p>\n<p><strong>Globe Life (GL)<\/strong> \u2014 TD Cowen raised its price target from $215.00 to $218.00, maintaining a Buy rating.<\/p>\n<p><strong>Gaming and Leisure Properties (GLPI)<\/strong> \u2014 Wells Fargo &amp; Company lowered its price target from $40.00 to $39.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Galaxy Digital (GLXY)<\/strong> \u2014 Piper Sandler lowered its price target from $25.00 to $24.00, maintaining an Overweight rating.<\/p>\n<p><strong>Gold.com (GOLD)<\/strong> \u2014 DA Davidson maintained its Buy rating with a price target of $60.00.<\/p>\n<p><strong>Goosehead Insurance (GSHD)<\/strong> \u2014 Keefe, Bruyette &amp; Woods lowered its price target from $66.00 to $60.00, maintaining an Outperform rating.<\/p>\n<p><strong>W.W. Grainger (GWW)<\/strong> \u2014 Morgan Stanley raised its price target from $1,400.00 to $1,590.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>W.W. Grainger (GWW)<\/strong> \u2014 Barclays raised its price target from $1,172.00 to $1,355.00, maintaining an Underweight rating.<\/p>\n<p><strong>Hyatt Hotels (H)<\/strong> \u2014 Sanford C. Bernstein raised its price target from $202.00 to $231.00, maintaining an Outperform rating.<\/p>\n<p><strong>Haemonetics (HAE)<\/strong> \u2014 Citizens Jmp raised its price target from $115.00 to $144.00, maintaining a Market Outperform rating.<\/p>\n<p><strong>Haemonetics (HAE)<\/strong> \u2014 Citigroup maintained its Market Outperform rating.<\/p>\n<p><strong>Halozyme Therapeutics (HALO)<\/strong> \u2014 TD Cowen maintained its Buy rating.<\/p>\n<p><strong>Hasbro (HAS)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $100.00 to $115.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Hasbro (HAS)<\/strong> \u2014 Roth Capital maintained its Buy rating and revised its price target from $125.00 to $136.00.<\/p>\n<p><strong>Hasbro (HAS)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $111.00 to $145.00, maintaining an Overweight rating.<\/p>\n<p><strong>HawkEye 360 (HAWK)<\/strong> \u2014 Morgan Stanley raised its price target from $25.00 to $26.00, maintaining an Overweight rating.<\/p>\n<p><strong>HudBay Minerals (HBM)<\/strong> \u2014 Barclays lowered its price target from $32.00 to $31.00, maintaining an Overweight rating.<\/p>\n<p><strong>Home Depot (HD)<\/strong> \u2014 Zelman &amp; Associates downgraded the stock to Underperform.<\/p>\n<p><strong>Home Depot (HD)<\/strong> \u2014 Citigroup downgraded the stock to Sell.<\/p>\n<p><strong>Herbalife (HLF)<\/strong> \u2014 Wells Fargo &amp; Company set a price target of $21.00.<\/p>\n<p><strong>Hilton Worldwide (HLT)<\/strong> \u2014 Sanford C. Bernstein raised its price target from $320.00 to $380.00, maintaining a Market Perform rating.<\/p>\n<p><strong>HMH (HMH)<\/strong> \u2014 Stifel Nicolaus lowered its price target from $28.00 to $25.00, maintaining a Buy rating.<\/p>\n<p><strong>HMH (HMH)<\/strong> \u2014 Citigroup maintained its Buy rating.<\/p>\n<p><strong>Hewlett Packard Enterprise (HPE)<\/strong> \u2014 Citigroup lowered its price target from $92.00 to $80.00, maintaining a Buy rating.<\/p>\n<p><strong>Hewlett Packard Enterprise (HPE)<\/strong> \u2014 Morgan Stanley lowered its price target from $72.00 to $64.00, maintaining an Overweight rating.<\/p>\n<p><strong>HP (HPQ)<\/strong> \u2014 Morgan Stanley raised its price target from $19.00 to $21.00, maintaining an Underweight rating.<\/p>\n<p><strong>Healthcare Realty Trust (HR)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $18.00 to $19.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Humana (HUM)<\/strong> \u2014 Royal Bank Of Canada upgraded the stock to Outperform and revised its price target from $415.00 to $563.00.<\/p>\n<p><strong>Humana (HUM)<\/strong> \u2014 Wells Fargo &amp; Company downgraded the stock to Underweight.<\/p>\n<p><strong>Humana (HUM)<\/strong> \u2014 William Blair initiated coverage with an Outperform rating.<\/p>\n<p><strong>Humana (HUM)<\/strong> \u2014 Cantor Fitzgerald initiated coverage with an Overweight rating.<\/p>\n<p><strong>Humana (HUM)<\/strong> \u2014 ThinkEquity initiated coverage with a Buy rating.<\/p>\n<p><strong>Humana (HUM)<\/strong> \u2014 TD Cowen upgraded the stock to Buy.<\/p>\n<p><strong>Humana (HUM)<\/strong> \u2014 KeyCorp downgraded the stock to Sector Weight.<\/p>\n<p><strong>Hut 8 (HUT)<\/strong> \u2014 Piper Sandler lowered its price target from $123.00 to $115.00, maintaining an Overweight rating.<\/p>\n<p><strong>Hancock Whitney (HWC)<\/strong> \u2014 Keefe, Bruyette &amp; Woods lowered its price target from $79.00 to $72.00, maintaining a Market Perform rating.<\/p>\n<p><strong>Installed Building Products (IBP)<\/strong> \u2014 Truist Financial raised its price target from $180.00 to $220.00, maintaining a Hold rating.<\/p>\n<p><strong>Installed Building Products (IBP)<\/strong> \u2014 Royal Bank Of Canada raised its price target from $194.00 to $215.00, maintaining a Sector Perform rating.<\/p>\n<p><strong>Intercontinental Exchange (ICE)<\/strong> \u2014 Argus raised its price target from $187.00 to $198.00, maintaining a Buy rating.<\/p>\n<p><strong>Intercontinental Hotels Group (IHG)<\/strong> \u2014 Sanford C. Bernstein raised its price target from $154.00 to $177.00, maintaining a Market Perform rating.<\/p>\n<p><strong>Illumina (ILMN)<\/strong> \u2014 Jefferies Financial Group set a price target of $235.00, maintaining a Hold rating.<\/p>\n<p><strong>Immunocore (IMCR)<\/strong> \u2014 BTIG Research maintained its Buy rating.<\/p>\n<p><strong>Immix Biopharma (IMMX)<\/strong> \u2014 HC Wainwright raised its price target from $25.00 to $27.00, maintaining a Buy rating.<\/p>\n<p><strong>Inhibrx Biosciences (INBX)<\/strong> \u2014 HC Wainwright lowered its price target from $245.00 to $220.00, maintaining a Buy rating.<\/p>\n<p><strong>Inter &amp; Co. Inc. (INTR)<\/strong> \u2014 The Goldman Sachs Group lowered its price target from $9.00 to $8.00, maintaining a Buy rating.<\/p>\n<p><strong>Innoviz Technologies (INVZ)<\/strong> \u2014 The Goldman Sachs Group lowered its price target from $0.40 to $0.20, maintaining a Neutral rating.<\/p>\n<p><strong>Samsara (IOT)<\/strong> \u2014 Truist Financial lowered its price target from $48.00 to $41.00, maintaining a Hold rating.<\/p>\n<p><strong>iQIYI (IQ)<\/strong> \u2014 Jefferies Financial Group set a price target of $1.19, maintaining a Buy rating.<\/p>\n<p><strong>Ingersoll Rand (IR)<\/strong> \u2014 Melius Research upgraded the stock to Buy, with a price target of $113.00.<\/p>\n<p><strong>Quince Therapeutics (IRLA)<\/strong> \u2014 Citizens Jmp raised its price target from $77.00 to $86.00, maintaining a Market Outperform rating.<\/p>\n<p><strong>Itau Unibanco (ITUB)<\/strong> \u2014 JPMorgan Chase &amp; Co. lowered its price target from $10.00 to $9.00, maintaining an Overweight rating.<\/p>\n<p><strong>Invivyd (IVVD)<\/strong> \u2014 BTIG Research maintained its Buy rating.<\/p>\n<p><strong>Janus Living (JAN)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $34.00 to $36.00, maintaining an Overweight rating.<\/p>\n<p><strong>Jade Biosciences (JBIO)<\/strong> \u2014 BTIG Research maintained its Buy rating.<\/p>\n<p><strong>Jade Biosciences (JBIO)<\/strong> \u2014 Guggenheim lowered its price target from $47.00 to $41.00, maintaining a Buy rating.<\/p>\n<p><strong>Jefferson Capital (JCAP)<\/strong> \u2014 Keefe, Bruyette &amp; Woods raised its price target from $30.00 to $32.00, maintaining an Outperform rating.<\/p>\n<p><strong>Jones Lang LaSalle (JLL)<\/strong> \u2014 Barclays raised its price target from $401.00 to $404.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Kraft Heinz (KHC)<\/strong> \u2014 Barclays lowered its price target from $25.00 to $24.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>KinderCare Learning Companies (KLC)<\/strong> \u2014 Barclays lowered its price target from $3.00 to $1.50, maintaining an Underweight rating.<\/p>\n<p><strong>Kennametal (KMT)<\/strong> \u2014 Morgan Stanley lowered its price target from $27.00 to $20.00, maintaining an Underweight rating.<\/p>\n<p><strong>Kinsale Capital Group (KNSL)<\/strong> \u2014 Morgan Stanley raised its price target from $350.00 to $400.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Kinetik (KNTK)<\/strong> \u2014 Wolfe Research upgraded the stock to Outperform.<\/p>\n<p><strong>Kinetik (KNTK)<\/strong> \u2014 Royal Bank Of Canada raised its price target from $58.00 to $62.00, maintaining an Outperform rating.<\/p>\n<p><strong>Coca Cola FEMSA (KOF)<\/strong> \u2014 Itau BBA Securities upgraded the stock to Strong-Buy.<\/p>\n<p><strong>Katapult (KPLT)<\/strong> \u2014 Stephens upgraded the stock to Overweight, with a price target of $15.00.<\/p>\n<p><strong>Kura Sushi USA (KRUS)<\/strong> \u2014 Northcoast Research downgraded the stock to Neutral.<\/p>\n<p><strong>Centrus Energy (LEU)<\/strong> \u2014 Cantor Fitzgerald initiated coverage with an Overweight rating and a price target of $130.00.<\/p>\n<p><strong>Lineage (LINE)<\/strong> \u2014 Truist Financial lowered its price target from $46.00 to $41.00, maintaining a Buy rating.<\/p>\n<p><strong>Lakefront Biotherapeutics American Depositary Shares (LKFT)<\/strong> \u2014 Morgan Stanley raised its price target from $26.00 to $27.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Eli Lilly and Company (LLY)<\/strong> \u2014 Barclays raised its price target from $1,400.00 to $1,550.00, maintaining an Overweight rating.<\/p>\n<p><strong>Lemonade (LMND)<\/strong> \u2014 Morgan Stanley lowered its price target from $48.00 to $45.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Lowe&#8217;s Companies (LOW)<\/strong> \u2014 Zelman &amp; Associates downgraded the stock to Underperform.<\/p>\n<p><strong>Larimar Therapeutics (LRMR)<\/strong> \u2014 Wedbush lowered its price target from $11.00 to $9.00, maintaining an Outperform rating.<\/p>\n<p><strong>Intuitive Machines (LUNR)<\/strong> \u2014 Canaccord Genuity Group lowered its price target from $39.00 to $38.00, maintaining a Buy rating.<\/p>\n<p><strong>LiveOne (LVO)<\/strong> \u2014 Freedom Broker lowered its price target from $7.00 to $5.00, maintaining a Buy rating.<\/p>\n<p><strong>Lexeo Therapeutics (LXEO)<\/strong> \u2014 Raymond James Financial maintained its Strong-Buy rating.<\/p>\n<p><strong>Marriott International (MAR)<\/strong> \u2014 Sanford C. Bernstein raised its price target from $445.00 to $479.00, maintaining an Outperform rating.<\/p>\n<p><strong>MARA (MARA)<\/strong> \u2014 Piper Sandler lowered its price target from $11.00 to $10.00, maintaining an Overweight rating.<\/p>\n<p><strong>Mobility Global (MBGL)<\/strong> \u2014 Citigroup raised its price target from $23.00 to $25.00, maintaining a Neutral rating.<\/p>\n<p><strong>MercadoLibre (MELI)<\/strong> \u2014 Susquehanna maintained its Positive rating.<\/p>\n<p><strong>Milestone Pharmaceuticals (MIST)<\/strong> \u2014 Piper Sandler issued a price target of $3.00, maintaining an Overweight rating.<\/p>\n<p><strong>Martin Marietta Materials (MLM)<\/strong> \u2014 Morgan Stanley lowered its price target from $639.00 to $590.00, maintaining an Overweight rating.<\/p>\n<p><strong>3M (MMM)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $195.00 to $205.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Merit Medical Systems (MMSI)<\/strong> \u2014 Raymond James Financial set a price target of $104.00, maintaining an Outperform rating.<\/p>\n<p><strong>Monopar Therapeutics (MNPR)<\/strong> \u2014 Morgan Stanley raised its price target from $130.00 to $133.00, maintaining an Overweight rating.<\/p>\n<p><strong>Marsh &amp; McLennan Companies (MRSH)<\/strong> \u2014 Morgan Stanley raised its price target from $190.00 to $215.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>MSC Income Fund (MSIF)<\/strong> \u2014 Keefe, Bruyette &amp; Woods lowered its price target from $15.50 to $15.00, maintaining an Outperform rating.<\/p>\n<p><strong>MasTec (MTZ)<\/strong> \u2014 Guggenheim lowered its price target from $518.00 to $335.00, maintaining a Buy rating.<\/p>\n<p><strong>SOLV Energy (MWH)<\/strong> \u2014 TD Cowen raised its price target from $35.00 to $37.00, maintaining a Buy rating.<\/p>\n<p><strong>KindlyMD (NAKA)<\/strong> \u2014 B. Riley Financial lowered its price target from $13.00 to $10.00, maintaining a Buy rating.<\/p>\n<p><strong>Navan (NAVN)<\/strong> \u2014 TD Cowen raised its price target from $30.00 to $32.00, maintaining a Buy rating.<\/p>\n<p><strong>National Bank (NBHC)<\/strong> \u2014 Hovde Group initiated coverage with an Outperform rating and a price target of $42.00.<\/p>\n<p><strong>Nebius Group (NBIS)<\/strong> \u2014 Citigroup lowered its price target from $265.00 to $215.00, maintaining a Buy rating.<\/p>\n<p><strong>National CineMedia (NCMI)<\/strong> \u2014 B. Riley Financial upgraded the stock to Buy and revised its price target from $2.50 to $3.00.<\/p>\n<p><strong>National CineMedia (NCMI)<\/strong> \u2014 National Bank Financial set a price target of $3.00.<\/p>\n<p><strong>NextDecade (NEXT)<\/strong> \u2014 TD Cowen raised its price target from $7.00 to $7.50, maintaining a Hold rating.<\/p>\n<p><strong>National Health Investors (NHI)<\/strong> \u2014 Wells Fargo &amp; Company lowered its price target from $68.00 to $65.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>NIQ Global Intelligence (NIQ)<\/strong> \u2014 Citigroup raised its price target from $16.00 to $19.50, maintaining a Neutral rating.<\/p>\n<p><strong>NIKE (NKE)<\/strong> \u2014 Cantor Fitzgerald maintained its Neutral rating with a price target of $38.00.<\/p>\n<p><strong>Nektar Therapeutics (NKTR)<\/strong> \u2014 Canaccord Genuity Group lowered its price target from $153.00 to $149.00, maintaining a Buy rating.<\/p>\n<p><strong>Newmark Group (NMRK)<\/strong> \u2014 Barclays lowered its price target from $20.00 to $14.00, maintaining an Overweight rating.<\/p>\n<p><strong>NNN REIT (NNN)<\/strong> \u2014 Wells Fargo &amp; Company lowered its price target from $43.00 to $42.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Northrop Grumman (NOC)<\/strong> \u2014 BTIG Research maintained its Buy rating.<\/p>\n<p><strong>NeuroPace (NPCE)<\/strong> \u2014 Wolfe Research downgraded the stock to Hold.<\/p>\n<p><strong>NeuroPace (NPCE)<\/strong> \u2014 Mizuho lowered its price target from $22.00 to $12.00, maintaining an Outperform rating.<\/p>\n<p><strong>NeuroPace (NPCE)<\/strong> \u2014 HC Wainwright lowered its price target from $20.00 to $12.00, maintaining a Buy rating.<\/p>\n<p><strong>NRG Energy (NRG)<\/strong> \u2014 BMO Capital Markets lowered its price target from $147.00 to $124.00, maintaining a Market Perform rating.<\/p>\n<p><strong>Insperity (NSP)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $38.00 to $45.00, maintaining an Underweight rating.<\/p>\n<p><strong>NetApp (NTAP)<\/strong> \u2014 Evercore maintained its Outperform rating.<\/p>\n<p><strong>Netskope (NTSK)<\/strong> \u2014 TD Cowen raised its price target from $19.00 to $25.00, maintaining a Buy rating.<\/p>\n<p><strong>NETSTREIT (NTST)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $20.00 to $21.00, maintaining an Overweight rating.<\/p>\n<p><strong>Nucor (NUE)<\/strong> \u2014 UBS Group upgraded the stock to Buy and revised its price target from $256.00 to $307.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Mizuho lowered its price target from $250.00 to $220.00, maintaining an Outperform rating.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 TD Cowen lowered its price target from $275.00 to $200.00, maintaining a Buy rating.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 UBS Group set a price target of $240.00, maintaining a Buy rating.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 CLSA initiated coverage with a Moderate Buy rating.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 CLSA set a price target of $255.00, maintaining an Outperform rating.<\/p>\n<p><strong>Realty Income (O)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $59.00 to $61.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>OFG Bancorp (OFG)<\/strong> \u2014 UBS Group initiated coverage with a Sell rating and a price target of $50.00.<\/p>\n<p><strong>Once Upon A Farm (OFRM)<\/strong> \u2014 Barclays lowered its price target from $19.00 to $11.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Omega Healthcare Investors (OHI)<\/strong> \u2014 Royal Bank Of Canada raised its price target from $51.00 to $52.00, maintaining a Sector Perform rating.<\/p>\n<p><strong>Omega Healthcare Investors (OHI)<\/strong> \u2014 Mizuho raised its price target from $46.00 to $49.00, maintaining a Neutral rating.<\/p>\n<p><strong>Omega Healthcare Investors (OHI)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $46.00 to $49.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Orion180 Insurance Group (OIG)<\/strong> \u2014 Raymond James Financial maintained its Market Perform rating.<\/p>\n<p><strong>Omada Health (OMDA)<\/strong> \u2014 JPMorgan Chase &amp; Co. lowered its price target from $30.00 to $25.00, maintaining an Overweight rating.<\/p>\n<p><strong>Ondas (ONDS)<\/strong> \u2014 Stifel Nicolaus lowered its price target from $18.00 to $15.00, maintaining a Buy rating.<\/p>\n<p><strong>Orrstown Financial Services (ORRF)<\/strong> \u2014 Raymond James Financial maintained its Market Perform rating.<\/p>\n<p><strong>Blue Owl Technology Finance (OTF)<\/strong> \u2014 Keefe, Bruyette &amp; Woods lowered its price target from $12.00 to $11.50, maintaining a Market Perform rating.<\/p>\n<p><strong>Ovintiv (OVV)<\/strong> \u2014 JPMorgan Chase &amp; Co. set a price target of $84.00.<\/p>\n<p><strong>Blue Owl Capital (OWL)<\/strong> \u2014 Mizuho initiated coverage with an Outperform rating and a price target of $13.00.<\/p>\n<p><strong>Owlet (OWLT)<\/strong> \u2014 TD Cowen lowered its price target from $10.00 to $4.00, maintaining a Buy rating.<\/p>\n<p><strong>Everpure (P)<\/strong> \u2014 Morgan Stanley raised its price target from $137.00 to $142.00, maintaining an Overweight rating.<\/p>\n<p><strong>Everpure (P)<\/strong> \u2014 Wedbush set a price target of $130.00, maintaining an Outperform rating.<\/p>\n<p><strong>PACS Group (PACS)<\/strong> \u2014 Royal Bank Of Canada raised its price target from $57.00 to $64.00, maintaining an Outperform rating.<\/p>\n<p><strong>Palo Alto Networks (PANW)<\/strong> \u2014 Cantor Fitzgerald maintained its Overweight rating with a price target of $425.00.<\/p>\n<p><strong>Palo Alto Networks (PANW)<\/strong> \u2014 TD Cowen maintained its Buy rating with a price target of $440.00.<\/p>\n<p><strong>Pro-Dex (PDEX)<\/strong> \u2014 Ascendiant Capital Markets raised its price target from $74.00 to $80.00, maintaining a Buy rating.<\/p>\n<p><strong>Principal Financial Group (PFG)<\/strong> \u2014 UBS Group initiated coverage with a Sell rating and a price target of $50.00.<\/p>\n<p><strong>Precigen (PGEN)<\/strong> \u2014 B. Riley Financial maintained its Buy rating and revised its price target from $12.00 to $11.00.<\/p>\n<p><strong>Palantir Technologies (PLTR)<\/strong> \u2014 Deutsche Bank set a price target of $248.00.<\/p>\n<p><strong>Palantir Technologies (PLTR)<\/strong> \u2014 Barclays set a price target of $248.00.<\/p>\n<p><strong>Palantir Technologies (PLTR)<\/strong> \u2014 Phillip Securities upgraded the stock to Strong-Buy.<\/p>\n<p><strong>Praxis Precision Medicines (PRAX)<\/strong> \u2014 Guggenheim raised its price target from $800.00 to $1,050.00, maintaining a Buy rating.<\/p>\n<p><strong>Praxis Precision Medicines (PRAX)<\/strong> \u2014 Robert W. Baird raised its price target from $514.00 to $568.00, maintaining an Outperform rating.<\/p>\n<p><strong>Prime Medicine (PRME)<\/strong> \u2014 HC Wainwright maintained its Buy rating with a price target of $8.00.<\/p>\n<p><strong>Palvella Therapeutics (PVLA)<\/strong> \u2014 Leerink Partners initiated coverage with an Outperform rating and a price target of $228.00.<\/p>\n<p><strong>Q2 (QTWO)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $76.00 to $82.00, maintaining an Overweight rating.<\/p>\n<p><strong>QXO (QXO)<\/strong> \u2014 Raymond James Financial set a price target of $21.00, maintaining an Outperform rating.<\/p>\n<p><strong>Roblox (RBLX)<\/strong> \u2014 Piper Sandler maintained its Neutral rating with a price target of $52.00.<\/p>\n<p><strong>RideNow Group (RDNW)<\/strong> \u2014 DA Davidson lowered its price target from $8.00 to $5.00, maintaining a Neutral rating.<\/p>\n<p><strong>Real REMAX Group (REAX)<\/strong> \u2014 Freedom Broker lowered its price target from $40.00 to $25.00, maintaining a Buy rating.<\/p>\n<p><strong>Replimune Group (REPL)<\/strong> \u2014 Piper Sandler raised its price target from $14.00 to $27.00, maintaining an Overweight rating.<\/p>\n<p><strong>Rithm Capital (RITM)<\/strong> \u2014 Piper Sandler maintained its Overweight rating.<\/p>\n<p><strong>Rivian Automotive (RIVN)<\/strong> \u2014 Citigroup lowered its price target from $18.00 to $14.50, maintaining a Neutral rating.<\/p>\n<p><strong>Rivian Automotive (RIVN)<\/strong> \u2014 DA Davidson maintained its Neutral rating with a price target of $15.00.<\/p>\n<p><strong>Suncrete (RMIX)<\/strong> \u2014 Robert W. Baird lowered its price target from $17.00 to $9.00, maintaining an Outperform rating.<\/p>\n<p><strong>Roivant Sciences (ROIV)<\/strong> \u2014 Guggenheim raised its price target from $46.00 to $48.00, maintaining a Buy rating.<\/p>\n<p><strong>Ross Stores (ROST)<\/strong> \u2014 Morgan Stanley raised its price target from $234.00 to $235.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Rapid Micro Biosystems (RPID)<\/strong> \u2014 Lake Street Capital downgraded the stock to Hold, with a price target of $0.75.<\/p>\n<p><strong>Revvity (RVTY)<\/strong> \u2014 KeyCorp maintained its Overweight rating with a price target of $200.00.<\/p>\n<p><strong>Revvity (RVTY)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $160.00 to $165.00, maintaining a Neutral rating.<\/p>\n<p><strong>Recursion Pharmaceuticals (RXRX)<\/strong> \u2014 JPMorgan Chase &amp; Co. lowered its price target from $10.00 to $7.00, maintaining an Overweight rating.<\/p>\n<p><strong>Ryan Specialty (RYAN)<\/strong> \u2014 Morgan Stanley raised its price target from $50.00 to $55.00, maintaining an Overweight rating.<\/p>\n<p><strong>Sana Biotechnology (SANA)<\/strong> \u2014 Citigroup issued a price target of $11.00, maintaining a Buy rating.<\/p>\n<p><strong>Sabra Healthcare REIT (SBRA)<\/strong> \u2014 Mizuho raised its price target from $21.00 to $22.00, maintaining a Neutral rating.<\/p>\n<p><strong>Sabra Healthcare REIT (SBRA)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $21.00 to $23.00, maintaining an Overweight rating.<\/p>\n<p><strong>SolarEdge Technologies (SEDG)<\/strong> \u2014 Wells Fargo &amp; Company lowered its price target from $36.00 to $26.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Super Group (SGHC) (SGHC)<\/strong> \u2014 Wells Fargo &amp; Company initiated coverage with an Equal Weight rating and a price target of $13.00.<\/p>\n<p><strong>Somnigroup International (SGI)<\/strong> \u2014 The Goldman Sachs Group initiated coverage with a Neutral rating and a price target of $72.00.<\/p>\n<p><strong>Sigma Lithium (SGML)<\/strong> \u2014 JPMorgan Chase &amp; Co. lowered its price target from $11.00 to $7.00, maintaining an Overweight rating.<\/p>\n<p><strong>SiteOne Landscape Supply (SITE)<\/strong> \u2014 Stifel Nicolaus raised its price target from $102.00 to $108.00, maintaining a Hold rating.<\/p>\n<p><strong>J. M. Smucker (SJM)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $149.00 to $150.00, maintaining an Overweight rating.<\/p>\n<p><strong>Skyward Specialty Insurance Group (SKWD)<\/strong> \u2014 TD Cowen raised its price target from $65.00 to $69.00, maintaining a Hold rating.<\/p>\n<p><strong>Summit Therapeutics (SMMT)<\/strong> \u2014 Barclays lowered its price target from $20.00 to $18.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Summit Therapeutics (SMMT)<\/strong> \u2014 Citigroup lowered its price target from $43.00 to $42.00, maintaining a Buy rating.<\/p>\n<p><strong>Semtech (SMTC)<\/strong> \u2014 UBS Group lowered its price target from $230.00 to $200.00, maintaining a Buy rating.<\/p>\n<p><strong>Semtech (SMTC)<\/strong> \u2014 Morgan Stanley lowered its price target from $205.00 to $176.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Spectrum Brands (SPB)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $85.00 to $87.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>SpaceX (SPCX)<\/strong> \u2014 Royal Bank Of Canada maintained its Outperform rating with a price target of $225.00.<\/p>\n<p><strong>SpaceX (SPCX)<\/strong> \u2014 Pivotal Research maintained its Buy rating.<\/p>\n<p><strong>SpaceX (SPCX)<\/strong> \u2014 Raymond James Financial maintained its Strong-Buy rating.<\/p>\n<p><strong>SpaceX (SPCX)<\/strong> \u2014 Sanford C. Bernstein maintained its Outperform rating.<\/p>\n<p><strong>SpaceX (SPCX)<\/strong> \u2014 Piper Sandler maintained its Neutral rating.<\/p>\n<p><strong>SpaceX (SPCX)<\/strong> \u2014 The Goldman Sachs Group maintained its Buy rating.<\/p>\n<p><strong>SiriusPoint (SPNT)<\/strong> \u2014 Raymond James Financial maintained its Market Perform rating.<\/p>\n<p><strong>SPX Technologies (SPXC)<\/strong> \u2014 TD Cowen upgraded the stock to Buy and revised its price target from $225.00 to $200.00.<\/p>\n<p><strong>Stag Industrial (STAG)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $38.00 to $39.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Stagwell (STGW)<\/strong> \u2014 Stonex Financial upgraded the stock to Strong-Buy.<\/p>\n<p><strong>Stagwell (STGW)<\/strong> \u2014 StoneX upgraded the stock to Buy, with a price target of $15.00.<\/p>\n<p><strong>Neuronetics (STIM)<\/strong> \u2014 William Blair initiated coverage with an Outperform rating.<\/p>\n<p><strong>Steel Dynamics (STLD)<\/strong> \u2014 UBS Group lowered its price target from $276.00 to $257.00, maintaining a Neutral rating.<\/p>\n<p><strong>Stantec (STN)<\/strong> \u2014 Stifel Nicolaus downgraded the stock to Hold.<\/p>\n<p><strong>BBB Foods (TBBB)<\/strong> \u2014 Itau BBA Securities downgraded the stock to Market Perform, with a price target of $74.00.<\/p>\n<p><strong>Telephone and Data Systems (TDS)<\/strong> \u2014 JPMorgan Chase &amp; Co. lowered its price target from $48.00 to $45.00, maintaining an Overweight rating.<\/p>\n<p><strong>Tidewater (TDW)<\/strong> \u2014 Barclays lowered its price target from $91.00 to $88.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Telecom Argentina Stet &#8211; France Telecom (TEO)<\/strong> \u2014 UBS Group lowered its price target from $16.50 to $15.00, maintaining a Buy rating.<\/p>\n<p><strong>Target (TGT)<\/strong> \u2014 Jefferies Financial Group maintained its Buy rating.<\/p>\n<p><strong>Target Hospitality (TH)<\/strong> \u2014 Morgan Stanley lowered its price target from $25.00 to $21.00, maintaining an Overweight rating.<\/p>\n<p><strong>Target Hospitality (TH)<\/strong> \u2014 Oppenheimer lowered its price target from $27.00 to $22.00, maintaining an Outperform rating.<\/p>\n<p><strong>The Hanover Insurance Group (THG)<\/strong> \u2014 Morgan Stanley raised its price target from $235.00 to $250.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>TJX Companies (TJX)<\/strong> \u2014 Morgan Stanley lowered its price target from $178.00 to $166.00, maintaining an Overweight rating.<\/p>\n<p><strong>TriNet Group (TNET)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $50.00 to $55.00, maintaining an Underweight rating.<\/p>\n<p><strong>Targa Resources (TRGP)<\/strong> \u2014 Stifel Nicolaus raised its price target from $335.00 to $340.00, maintaining a Buy rating.<\/p>\n<p><strong>Trustmark (TRMK)<\/strong> \u2014 Keefe, Bruyette &amp; Woods raised its price target from $50.00 to $54.00, maintaining a Market Perform rating.<\/p>\n<p><strong>TransUnion (TRU)<\/strong> \u2014 Mizuho raised its price target from $74.00 to $78.00, maintaining a Neutral rating.<\/p>\n<p><strong>TWFG (TWFG)<\/strong> \u2014 Morgan Stanley raised its price target from $31.00 to $32.00, maintaining an Overweight rating.<\/p>\n<p><strong>Twist Bioscience (TWST)<\/strong> \u2014 Barclays lowered its price target from $215.00 to $130.00, maintaining an Overweight rating.<\/p>\n<p><strong>Texas Roadhouse (TXRH)<\/strong> \u2014 Gordon Haskett upgraded the stock to Buy, with a price target of $220.00.<\/p>\n<p><strong>Travelzoo (TZOO)<\/strong> \u2014 Ascendiant Capital Markets lowered its price target from $20.00 to $18.00, maintaining a Buy rating.<\/p>\n<p><strong>United Dominion Realty Trust (UDR)<\/strong> \u2014 Zelman &amp; Associates upgraded the stock to Outperform, with a price target of $41.25.<\/p>\n<p><strong>Ulta Beauty (ULTA)<\/strong> \u2014 BMO Capital Markets raised its price target from $580.00 to $665.00, maintaining a Market Perform rating.<\/p>\n<p><strong>USA Rare Earth (USAR)<\/strong> \u2014 William Blair downgraded the stock to Market Perform.<\/p>\n<p><strong>VersaBank (VBNK)<\/strong> \u2014 Roth Capital maintained its Buy rating and revised its price target from $28.00 to $32.00.<\/p>\n<p><strong>Viking (VIK)<\/strong> \u2014 Mizuho upgraded the stock to Outperform, with a price target of $120.00.<\/p>\n<p><strong>Telefonica Brasil (VIV)<\/strong> \u2014 UBS Group upgraded the stock to Neutral.<\/p>\n<p><strong>Vivmark Residential Common Shares of Beneficial Interest (VMRK)<\/strong> \u2014 Royal Bank Of Canada raised its price target from $67.00 to $68.00, maintaining a Sector Perform rating.<\/p>\n<p><strong>Corporacion Inmobiliaria Vesta (VTMX)<\/strong> \u2014 UBS Group raised its price target from $43.00 to $47.00, maintaining a Buy rating.<\/p>\n<p><strong>Ventas (VTR)<\/strong> \u2014 Mizuho lowered its price target from $104.00 to $101.00, maintaining an Outperform rating.<\/p>\n<p><strong>Ventas (VTR)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $96.00 to $102.00, maintaining an Overweight rating.<\/p>\n<p><strong>Welltower (WELL)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $268.00 to $283.00, maintaining an Overweight rating.<\/p>\n<p><strong>Welltower (WELL)<\/strong> \u2014 Mizuho raised its price target from $260.00 to $270.00, maintaining an Outperform rating.<\/p>\n<p><strong>Western Midstream Partners (WES)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $46.00 to $47.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>W.P. Carey (WPC)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $73.00 to $74.00, maintaining an Overweight rating.<\/p>\n<p><strong>Wise Group (WSE)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $17.70 to $17.80, maintaining an Overweight rating.<\/p>\n<p><strong>Williams-Sonoma (WSM)<\/strong> \u2014 Telsey Advisory Group set a price target of $285.00, maintaining an Outperform rating.<\/p>\n<p><strong>Watsco (WSO)<\/strong> \u2014 Morgan Stanley raised its price target from $330.00 to $340.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Willis Towers Watson Public (WTW)<\/strong> \u2014 Morgan Stanley raised its price target from $325.00 to $350.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>WhiteFiber (WYFI)<\/strong> \u2014 Cantor Fitzgerald lowered its price target from $36.00 to $24.00, maintaining an Overweight rating.<\/p>\n<p><strong>X-Energy (XE)<\/strong> \u2014 Piper Sandler raised its price target from $8.00 to $9.00, maintaining an Underweight rating.<\/p>\n<p><strong>DENTSPLY SIRONA (XRAY)<\/strong> \u2014 UBS Group lowered its price target from $17.00 to $13.00, maintaining a Buy rating.<\/p>\n<p><strong>Yarrow Bioscience (YARW)<\/strong> \u2014 Jefferies Financial Group set a price target of $40.00, maintaining a Buy rating.<\/p>\n<p><strong>YETI (YETI)<\/strong> \u2014 The Goldman Sachs Group downgraded the stock to Neutral and revised its price target from $57.00 to $41.00.<\/p>\n<p><strong>York Space Systems (YSS)<\/strong> \u2014 Citigroup lowered its price target from $10.00 to $8.00, maintaining a Buy rating.<\/p>\n<p><strong>York Space Systems (YSS)<\/strong> \u2014 Canaccord Genuity Group upgraded the stock to Buy and revised its price target from $13.50 to $9.00.<\/p>\n<p><strong>Zimmer Biomet (ZBH)<\/strong> \u2014 BMO Capital Markets lowered its price target from $102.00 to $101.00, maintaining a Market Perform rating.<\/p>\n<p><strong>Zimmer Biomet (ZBH)<\/strong> \u2014 Stifel Nicolaus raised its price target from $125.00 to $140.00, maintaining a Buy rating.<\/p>\n<p><strong>Zevra Therapeutics (ZVRA)<\/strong> \u2014 Guggenheim lowered its price target from $23.00 to $18.00, maintaining a Buy rating.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Analyst Ratings (USA) Applied Aerospace &amp; Defense (AADX) \u2014 Jefferies Financial Group downgraded the stock to Hold and revised its price target from $20.00&hellip;<\/p>\n","protected":false},"author":3,"featured_media":73674,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-77151","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>American Analyst Ratings Updates: November 16th, 2026 | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"American Analyst Ratings Updates: November 16th, 2026\" \/>\n<meta property=\"og:description\" content=\"Analyst Ratings (USA) Applied Aerospace &amp; Defense (AADX) \u2014 Jefferies Financial Group downgraded the stock to Hold and revised its price target from $20.00&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-17T20:01:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2026\/05\/Spacexx.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1195\" \/>\n\t<meta property=\"og:image:height\" content=\"474\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"26 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"American Analyst Ratings Updates: November 16th, 2026\",\"datePublished\":\"2026-11-17T20:01:30+00:00\",\"dateModified\":\"2026-11-17T20:01:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/\"},\"wordCount\":5407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/\",\"name\":\"American Analyst Ratings Updates: November 16th, 2026 | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2026-11-17T20:01:30+00:00\",\"dateModified\":\"2026-11-17T20:01:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"American Analyst Ratings Updates: November 16th, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"American Analyst Ratings Updates: November 16th, 2026 | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/","og_locale":"en_US","og_type":"article","og_title":"American Analyst Ratings Updates: November 16th, 2026","og_description":"Analyst Ratings (USA) Applied Aerospace &amp; Defense (AADX) \u2014 Jefferies Financial Group downgraded the stock to Hold and revised its price target from $20.00&hellip;","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2026-11-17T20:01:30+00:00","og_image":[{"width":1195,"height":474,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2026\/05\/Spacexx.jpg","type":"image\/jpeg"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"26 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"American Analyst Ratings Updates: November 16th, 2026","datePublished":"2026-11-17T20:01:30+00:00","dateModified":"2026-11-17T20:01:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/"},"wordCount":5407,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/","name":"American Analyst Ratings Updates: November 16th, 2026 | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2026-11-17T20:01:30+00:00","dateModified":"2026-11-17T20:01:30+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-16th-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"American Analyst Ratings Updates: November 16th, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/77151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=77151"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/77151\/revisions"}],"predecessor-version":[{"id":77153,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/77151\/revisions\/77153"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/73674"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=77151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=77151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=77151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}